22nd Century Group, Inc.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, PM has a market cap of 264.19B. Regarding current trading prices, XXII is priced at $1.05, while PM trades at $169.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas PM's P/E ratio is 26.73. In terms of profitability, XXII's ROE is +11.91%, compared to PM's ROE of -0.72%. Regarding short-term risk, XXII is more volatile compared to PM. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, MO has a market cap of 100.12B. Regarding current trading prices, XXII is priced at $1.05, while MO trades at $59.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas MO's P/E ratio is 9.97. In terms of profitability, XXII's ROE is +11.91%, compared to MO's ROE of -3.34%. Regarding short-term risk, XXII is more volatile compared to MO. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, BTI has a market cap of 91.35B. Regarding current trading prices, XXII is priced at $1.05, while BTI trades at $41.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas BTI's P/E ratio is 23.01. In terms of profitability, XXII's ROE is +11.91%, compared to BTI's ROE of -0.26%. Regarding short-term risk, XXII is more volatile compared to BTI. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, BTAFF has a market cap of 90.69B. Regarding current trading prices, XXII is priced at $1.05, while BTAFF trades at $41.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas BTAFF's P/E ratio is 22.84. In terms of profitability, XXII's ROE is +11.91%, compared to BTAFF's ROE of -0.27%. Regarding short-term risk, XXII is more volatile compared to BTAFF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, JAPAY has a market cap of 55.43B. Regarding current trading prices, XXII is priced at $1.05, while JAPAY trades at $15.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas JAPAY's P/E ratio is 44.60. In terms of profitability, XXII's ROE is +11.91%, compared to JAPAY's ROE of +0.08%. Regarding short-term risk, XXII is more volatile compared to JAPAY. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, JAPAF has a market cap of 51.75B. Regarding current trading prices, XXII is priced at $1.05, while JAPAF trades at $29.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas JAPAF's P/E ratio is 41.64. In terms of profitability, XXII's ROE is +11.91%, compared to JAPAF's ROE of +0.08%. Regarding short-term risk, XXII is more volatile compared to JAPAF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, IMBBY has a market cap of 33.79B. Regarding current trading prices, XXII is priced at $1.05, while IMBBY trades at $40.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas IMBBY's P/E ratio is 10.13. In terms of profitability, XXII's ROE is +11.91%, compared to IMBBY's ROE of +0.46%. Regarding short-term risk, XXII is more volatile compared to IMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, IMBBF has a market cap of 33.36B. Regarding current trading prices, XXII is priced at $1.05, while IMBBF trades at $39.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas IMBBF's P/E ratio is 10.39. In terms of profitability, XXII's ROE is +11.91%, compared to IMBBF's ROE of +0.46%. Regarding short-term risk, XXII is more volatile compared to IMBBF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, SWMAY has a market cap of 16.07B. Regarding current trading prices, XXII is priced at $1.05, while SWMAY trades at $10.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas SWMAY's P/E ratio is 27.82. In terms of profitability, XXII's ROE is +11.91%, compared to SWMAY's ROE of N/A. Regarding short-term risk, XXII is more volatile compared to SWMAY. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, SMORF has a market cap of 7.46B. Regarding current trading prices, XXII is priced at $1.05, while SMORF trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas SMORF's P/E ratio is 40.81. In terms of profitability, XXII's ROE is +11.91%, compared to SMORF's ROE of +0.07%. Regarding short-term risk, XXII is less volatile compared to SMORF. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, VGR has a market cap of 2.36B. Regarding current trading prices, XXII is priced at $1.05, while VGR trades at $14.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas VGR's P/E ratio is 11.90. In terms of profitability, XXII's ROE is +11.91%, compared to VGR's ROE of -0.27%. Regarding short-term risk, XXII is more volatile compared to VGR. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, PHJMF has a market cap of 2.33B. Regarding current trading prices, XXII is priced at $1.05, while PHJMF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas PHJMF's P/E ratio is 2.00. In terms of profitability, XXII's ROE is +11.91%, compared to PHJMF's ROE of +0.23%. Regarding short-term risk, XXII is less volatile compared to PHJMF. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, RLX has a market cap of 2.28B. Regarding current trading prices, XXII is priced at $1.05, while RLX trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas RLX's P/E ratio is 31.25. In terms of profitability, XXII's ROE is +11.91%, compared to RLX's ROE of +0.04%. Regarding short-term risk, XXII is more volatile compared to RLX. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, PHPMF has a market cap of 1.52B. Regarding current trading prices, XXII is priced at $1.05, while PHPMF trades at $795.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas PHPMF's P/E ratio is 14.41. In terms of profitability, XXII's ROE is +11.91%, compared to PHPMF's ROE of +0.46%. Regarding short-term risk, XXII is more volatile compared to PHPMF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, UVV has a market cap of 1.43B. Regarding current trading prices, XXII is priced at $1.05, while UVV trades at $57.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas UVV's P/E ratio is 11.55. In terms of profitability, XXII's ROE is +11.91%, compared to UVV's ROE of +0.09%. Regarding short-term risk, XXII is more volatile compared to UVV. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, TPB has a market cap of 1.34B. Regarding current trading prices, XXII is priced at $1.05, while TPB trades at $74.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas TPB's P/E ratio is 29.54. In terms of profitability, XXII's ROE is +11.91%, compared to TPB's ROE of +0.22%. Regarding short-term risk, XXII is more volatile compared to TPB. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, STBGY has a market cap of 1.16B. Regarding current trading prices, XXII is priced at $1.05, while STBGY trades at $7.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas STBGY's P/E ratio is 8.58. In terms of profitability, XXII's ROE is +11.91%, compared to STBGY's ROE of +0.10%. Regarding short-term risk, XXII is more volatile compared to STBGY. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, SNDVF has a market cap of 1.16B. Regarding current trading prices, XXII is priced at $1.05, while SNDVF trades at $14.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas SNDVF's P/E ratio is 8.53. In terms of profitability, XXII's ROE is +11.91%, compared to SNDVF's ROE of +0.10%. Regarding short-term risk, XXII is more volatile compared to SNDVF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, GDNGY has a market cap of 1.14B. Regarding current trading prices, XXII is priced at $1.05, while GDNGY trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas GDNGY's P/E ratio is 39.67. In terms of profitability, XXII's ROE is +11.91%, compared to GDNGY's ROE of +0.01%. Regarding short-term risk, XXII is less volatile compared to GDNGY. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, GGNPF has a market cap of 1.12B. Regarding current trading prices, XXII is priced at $1.05, while GGNPF trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas GGNPF's P/E ratio is 29.00. In terms of profitability, XXII's ROE is +11.91%, compared to GGNPF's ROE of +0.01%. Regarding short-term risk, XXII is more volatile compared to GGNPF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, KCIGF has a market cap of 828.00M. Regarding current trading prices, XXII is priced at $1.05, while KCIGF trades at $300.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas KCIGF's P/E ratio is 8.83. In terms of profitability, XXII's ROE is +11.91%, compared to KCIGF's ROE of +0.14%. Regarding short-term risk, XXII is more volatile compared to KCIGF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, ISPR has a market cap of 172.99M. Regarding current trading prices, XXII is priced at $1.05, while ISPR trades at $3.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas ISPR's P/E ratio is -7.39. In terms of profitability, XXII's ROE is +11.91%, compared to ISPR's ROE of -0.92%. Regarding short-term risk, XXII is more volatile compared to ISPR. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, PYYX has a market cap of 94.00M. Regarding current trading prices, XXII is priced at $1.05, while PYYX trades at $3.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas PYYX's P/E ratio is 9.79. In terms of profitability, XXII's ROE is +11.91%, compared to PYYX's ROE of +0.07%. Regarding short-term risk, XXII is more volatile compared to PYYX. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, CHUC has a market cap of 22.59M. Regarding current trading prices, XXII is priced at $1.05, while CHUC trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas CHUC's P/E ratio is -9.05. In terms of profitability, XXII's ROE is +11.91%, compared to CHUC's ROE of +4.44%. Regarding short-term risk, XXII is more volatile compared to CHUC. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, GRAM has a market cap of 10.93M. Regarding current trading prices, XXII is priced at $1.05, while GRAM trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas GRAM's P/E ratio is -0.09. In terms of profitability, XXII's ROE is +11.91%, compared to GRAM's ROE of +2.93%. Regarding short-term risk, XXII is less volatile compared to GRAM. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, KAVL has a market cap of 6.82M. Regarding current trading prices, XXII is priced at $1.05, while KAVL trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas KAVL's P/E ratio is -0.46. In terms of profitability, XXII's ROE is +11.91%, compared to KAVL's ROE of -0.70%. Regarding short-term risk, XXII is more volatile compared to KAVL. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, GGII has a market cap of 6.41M. Regarding current trading prices, XXII is priced at $1.05, while GGII trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas GGII's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to GGII's ROE of -0.51%. Regarding short-term risk, XXII is less volatile compared to GGII. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, VAPR has a market cap of 4.34M. Regarding current trading prices, XXII is priced at $1.05, while VAPR trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas VAPR's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to VAPR's ROE of +0.95%. Regarding short-term risk, XXII is less volatile compared to VAPR. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, VPRB has a market cap of 3.33M. Regarding current trading prices, XXII is priced at $1.05, while VPRB trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas VPRB's P/E ratio is -3.63. In terms of profitability, XXII's ROE is +11.91%, compared to VPRB's ROE of +0.12%. Regarding short-term risk, XXII is more volatile compared to VPRB. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, WSRRF has a market cap of 2.10M. Regarding current trading prices, XXII is priced at $1.05, while WSRRF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas WSRRF's P/E ratio is -2.00. In terms of profitability, XXII's ROE is +11.91%, compared to WSRRF's ROE of +1.29%. Regarding short-term risk, XXII is more volatile compared to WSRRF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, LBRG has a market cap of 2.08M. Regarding current trading prices, XXII is priced at $1.05, while LBRG trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas LBRG's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to LBRG's ROE of -0.23%. Regarding short-term risk, XXII is less volatile compared to LBRG. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, TOBAF has a market cap of 1.61M. Regarding current trading prices, XXII is priced at $1.05, while TOBAF trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas TOBAF's P/E ratio is -0.65. In terms of profitability, XXII's ROE is +11.91%, compared to TOBAF's ROE of +0.61%. Regarding short-term risk, XXII is more volatile compared to TOBAF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, CBDW has a market cap of 879110.00. Regarding current trading prices, XXII is priced at $1.05, while CBDW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas CBDW's P/E ratio is -0.11. In terms of profitability, XXII's ROE is +11.91%, compared to CBDW's ROE of +2.31%. Regarding short-term risk, XXII is less volatile compared to CBDW. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, HUMBF has a market cap of 521590.00. Regarding current trading prices, XXII is priced at $1.05, while HUMBF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas HUMBF's P/E ratio is -0.04. In terms of profitability, XXII's ROE is +11.91%, compared to HUMBF's ROE of -1.03%. Regarding short-term risk, XXII is more volatile compared to HUMBF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, VPOR has a market cap of 273017.00. Regarding current trading prices, XXII is priced at $1.05, while VPOR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas VPOR's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to VPOR's ROE of +0.00%. Regarding short-term risk, XXII is less volatile compared to VPOR. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, IDLSF has a market cap of 80117.00. Regarding current trading prices, XXII is priced at $1.05, while IDLSF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas IDLSF's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to IDLSF's ROE of N/A. Regarding short-term risk, XXII is more volatile compared to IDLSF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, MEDH has a market cap of 67390.00. Regarding current trading prices, XXII is priced at $1.05, while MEDH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas MEDH's P/E ratio is -0.06. In terms of profitability, XXII's ROE is +11.91%, compared to MEDH's ROE of -0.03%. Regarding short-term risk, XXII is less volatile compared to MEDH. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, GNLN has a market cap of 60860.00. Regarding current trading prices, XXII is priced at $1.05, while GNLN trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas GNLN's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to GNLN's ROE of -2.46%. Regarding short-term risk, XXII is more volatile compared to GNLN. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, ASHI has a market cap of 9205.00. Regarding current trading prices, XXII is priced at $1.05, while ASHI trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas ASHI's P/E ratio is -0.39. In terms of profitability, XXII's ROE is +11.91%, compared to ASHI's ROE of +0.12%. Regarding short-term risk, XXII is less volatile compared to ASHI. This indicates potentially lower risk in terms of short-term price fluctuations for XXII.

XXII plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XXII stands at 2.49M. In comparison, SWMAF comparison data is unavailable. Regarding current trading prices, XXII is priced at $1.05, while SWMAF trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XXII currently has a P/E ratio of -0.01, whereas SWMAF's P/E ratio is N/A. In terms of profitability, XXII's ROE is +11.91%, compared to SWMAF's ROE of N/A. Regarding short-term risk, XXII is more volatile compared to SWMAF. This indicates potentially higher risk in terms of short-term price fluctuations for XXII.